The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia

About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a <i>TP53</i> mutation (<i>mTP53</i>-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall survival...

Full description

Bibliographic Details

Published in:	Hemato
Main Authors:	Rory M. Shallis, Maximilian Stahl, Jan Philipp Bewersdorf, Amer M. Zeidan
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Subjects:	acute myeloid leukemia AML leukemia p53 <i>TP53</i>
Online Access:	https://www.mdpi.com/2673-6357/2/4/51